Case File
efta-01368644DOJ Data Set 10OtherEFTA01368644
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01368644
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
Proton therapy bonds
Area of expertise: Private markets
Theme: Sources of current income
rew
— The Provision Center for Proton Therapy (PCPT) is an ancillary healthcare facility providing cutting edge proton therapy treatment to cancer
patients in Knoxville, Tennessee
— The bonds were issued through the Health, Education & Housing Facilities Board of the County of Knox, Tennessee with a 20 year fully
amortizing term maturing in 2034. They are secured by a first mortgage on all property, plant and equipment comprising the project as well
as a pledge of gross revenues
— The amortization profile of the bonds provides a WAL of 6 years for the 2025 bonds and 16 years for the 2034 bonds
— Debt service coverage ratio is expected to climb to 1.75x by the end of 2015
— Risks: Interest rate risk, credit risk of issuer, medical reimbursement risk
Implementation
Bond structure:
Maturity
Par/mm
Coupon
Average life Turbo A/L
5/1/2034
5/1/2025
75.60
53.97
6.00%
9/19/2030
8/1/2020
5.25%
11/4/2020
n.a.
— Unlevered, the bonds provide a tax exempt return of
approximately 5-6% with upside potential once the project is
stabilized
— The tax exempt municipal bonds backed by the fully
stabilized proton therapy center in Jacksonville, FL, recently
traded at 3.60% yield to worst, illustrating the value the
market assigns to a stabilized project
— Applying TRS leverage, an investor can receive mid to high
teens in taxable interest
— For investors that value the tax exempt income, DB can
utilize a Senior/Sub trust structure to achieve low double
digit tax exempt yield
Deutsche Asset
e,
Mana9eive
Credit strengths
Timeline
Business
model
Protected
market share
Management
team
Operating
results
Project completed on time and budget. Ramp-up accelerating
with all three initial treatment rooms operational, partially
mitigating stabilization risk
Requires 8.8% market share (515 annual patients) of primary
service area proton-eligible patients to reach breakeven, and just
2.3% when extended to secondary service area
Provided through restrictive state certificate of need process.
Strong location on a mature cancer-care medical campus shared
with clinical partners. Nearest competitor over 500 miles away
Considerable experience managing new medical technologies
from both a facilities management and reimbursement
development standpoint
Impressive YTD operating results with the May through July
period producing above budget patient volume, net patient
revenues and cash collections, offsetting initial ramp off softness
For U.S. Key Client Partners (KCP) Clients Only
17
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
CONFIDENTIAL
DB-SDNY-0060508
SDNY GM_00206692
EFTA01368644
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.